In all-comer cohort of immunocompetent individuals at risk of contracting symptomatic COVID-19 in their everyday social interactions, participants receiving pemivibart experienced a 1.9% rate of ...

Texas Attorney General Ken Paxton's recent lawsuit against Pfizer has included a sweep of statements about the efficacy of its COVID-19 vaccine and the drug company's efforts to bring it to public ...

Researchers provided comprehensive evidence of the benefits of statin use in elderly patients, addressing longstanding uncertainties. The robust evidence demonstrated that continuous statin therapy ...

Dear Dr. Roach: A cardiologist recently suggested that I should consider taking a statin because of my “borderline” cholesterol level. So, I took a dive into the details of statin therapy. I learned ...

Statins Relative Risk Reduction: Statin medications are prescribed to reduce the risk of heart disease and heart attack. However, their benefits vary from person to person. Let us explain them.

PLACE AT 930, SO WITH WARMER, SUNNIER DAYS AHEAD, A LOT OF PARENTS AND CHILDREN WILL BE OUT ENJOYING YOUTH SPORTS THIS WEEKEND AND SOME NEW RESEARCH SUGGESTS THAT ONE SPORT WILL BE SAFER THANKS TO A ...

The blockbuster diabetes and weight loss drug semaglutide (Wegovy, Ozempic, Rybelsus) reduced the relative risk of heart attack, stroke, or cardiovascular deaths by 20 percent in high-risk patients ...

Semaglutide 2.4 mg could prevent nearly 2 million major cardiac events and over 1 million deaths in eligible patients. Uptake of semaglutide remains low due to cost, supply issues, and payer approval ...

NEW ORLEANS — The first global randomized trial of the PCSK9 inhibitor evolocumab for the prevention of a primary major adverse cardiovascular event (MACE) found a relative reduction in risk similar ...

This story is the first in a series called "Ozempic: Weighing the Risks and Benefits." It was produced in part through a grant from the NIHCM Foundation. When the final results of the SELECT trial ...

CKD patients face higher CVD risk, with dyslipidemia differing from the general population, necessitating tailored lipid ...